Can Creative Proteomics support anti-infective drugs not listed on this page?

Yes. Creative Proteomics can support custom method development, targeted quantification, metabolite identification, biomarker panel design, PK sample analysis, and integrated DMPK bioanalytical workflows for known, emerging, or proprietary anti-infective compounds.

Which analytical services are relevant to anti-infective drug studies?

Relevant services may include LC-MS/MS bioanalysis, parent drug and metabolite quantification, PK sample analysis, metabolite identification, metabolite profiling, stability-indicating assay development, targeted metabolomics, biomarker analysis, cytokine and immune marker measurement, DDI or transporter-related support, and multi-analyte panel development.

Drug Library Category

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Anti-Infective Drugs DMPK and Bioanalytical Services

Q: Which anti-infective drug classes are included?

This category page covers antibiotics, antiviral drugs, antifungal agents, antiparasitic drugs, and related anti-infective compounds.

Creative Proteomics provides DMPK, bioanalytical, metabolite profiling, and biomarker-related support for anti-infective drug research. This section of our drug library helps researchers explore analytical service options for antibiotics, antiviral drugs, antifungal agents, antiparasitic drugs, and related compounds.

Anti-infective drug studies often require more than parent-drug quantification alone. Depending on the drug class and study objective, researchers may need to evaluate metabolites, degradation products, renal clearance, tissue exposure, intracellular active forms, host-response biomarkers, or pathogen-associated readouts.

Explore Anti-Infective Drug Classes Discuss Your Study

Drug-Centered EntryStart from class, parent drug, metabolite, or response question.

Mechanism-AwareConnect exposure with infection-related pathways and biomarkers.

Service-MatchedMap needs to quantification, MetID, stability, and PK support.

Anti-Infective Study Logic

💊

Parent Drug / Drug ClassAntibiotics, antivirals, antifungals, antiparasitics

🧪

Metabolites & Degradation ProductsActive forms, hydrolysis products, conjugates, phosphorylated forms

📈

PK / Exposure PatternPlasma, urine, tissue, intracellular, infection-site exposure

🧬

Mechanism & ResponsePathogen burden, inflammation, immune activation, biomarkers

Explore Subcategories

Navigate Anti-Infective Drug Classes

Access our targeted bioanalytical and DMPK workflows tailored to specific anti-infective mechanisms, encompassing specialized screening protocols for leading antibacterial, antiviral, antifungal, and antiparasitic therapeutics.

🧫

Antibiotics

Explore DMPK and bioanalytical support for antibacterial drug classes, including exposure, renal excretion, hydrolysis, stability, and inflammation-linked readouts.

β-LactamsMacrolidesFluoroquinolonesAminoglycosides

Explore Antibiotics →

🦠

Antiviral Drugs

Support for parent-drug analysis, active metabolite quantification, intracellular exposure, viral-response readouts, and immune-response biomarkers.

Nucleoside AnalogsProtease InhibitorsDAAsNeuraminidase Inhibitors

Explore Antiviral Drugs →

🍄

Antifungal Drugs

Bioanalytical support for parent-drug exposure, tissue distribution, CYP-related metabolism, interaction potential, and matrix-specific method development.

AzolesEchinocandinsPolyenesAllylamines

Explore Antifungal Drugs →

Common Research Questions

What Researchers Need to Resolve

Anti-infective projects often start with a specific analytical or mechanistic question. These questions guide whether a study requires targeted quantification, MetID, stability-aware method development, biomarker analysis, or an integrated PK/PD workflow.

Parent drug or metabolite?Are the relevant analytes limited to the parent drug, or should metabolites, degradation products, or active intracellular forms also be included?

Renal clearance involved?Does the drug require urine-based analysis because renal excretion is a major disposition route?

Tissue penetration?Is tissue exposure important for evaluating drug concentration at infection-related sites?

Active intracellular forms?Do antiviral or related compounds require intracellular active metabolite or phosphorylated-form analysis?

Degradation products?Are instability or hydrolysis products likely to interfere with accurate parent-drug quantification?

Biomarker-linked response?Are host-response markers, pathogen-associated readouts, cytokines, bacterial burden, or viral load needed alongside exposure data?

Exposure • Mechanism • Response

Connecting Drug Exposure with Anti-Infective Mechanism and Response

Measuring parent-drug or metabolite concentration provides one part of the picture. Many anti-infective studies also require pathway-associated readouts to interpret whether exposure aligns with expected activity, pathogen response, or host immune signaling.

Exposure LayerParent drug, metabolites, intracellular active forms, tissue concentration

→

Mechanism LayerCell wall synthesis, protein synthesis, viral replication, ergosterol pathway

Disposition ContextRenal clearance, tissue penetration, CYP metabolism, degradation products

→

Response LayerPathogen burden, cytokines, interferon markers, immune activation

Analytical NeedLC-MS/MS quantification, MetID, stability profiling, biomarker panels

→

Study InterpretationExposure-response context, PK/PD support, pathway-linked readouts

Example Pathway and Response Readouts

Research Focus	Potential Readouts
Bacterial infection response	CRP, IL-6, TNF-α, WBC-related indicators, bacterial burden
Viral response studies	Viral load, IFN-α, IFN-γ, CD4+ T cell-related readouts
Antiviral intracellular activity	Active metabolites, phosphorylated forms, intracellular exposure
Renal clearance-related studies	Parent drug and metabolite levels in excretion-focused workflows
Fungal or parasitic response	Parent-drug exposure, metabolite profiling, host–pathogen response markers

Bioanalytical and DMPK Service Capabilities

Service Modules for Anti-Infective Drug Studies

Our modular bioanalytical platform translates complex anti-infective challenges into targeted testing pathways, delivering high-sensitivity assays for absolute quantification, metabolic clearance, and degradation kinetics.

Parent Drug and Metabolite Quantification

Targeted quantification of antibiotics, antiviral drugs, antifungal agents, antiparasitic compounds, and related analytes using study-specific workflows.

Parent-drug concentration measurement
Metabolite quantification
Parent–metabolite ratio analysis
Time-course sample analysis

PK and Exposure Assessment

Support for exposure questions that vary by drug class, matrix, and site of activity.

Plasma and serum exposure
Urinary excretion analysis
Tissue or infection-site concentration
Intracellular exposure when relevant

Metabolite Identification and Profiling

Clarify how anti-infective drugs are transformed in biological systems.

Phase I / II metabolite support
Hydrolysis and oxidation products
Active or low-abundance metabolites
Suspected metabolite confirmation

Stability and Degradation Product Analysis

Separate true biological metabolites from degradation-related products or sample-handling artifacts.

Stability-aware method development
Degradation product profiling
Stability-indicating assays
Support for labile compounds

Integrated Analysis

Why Anti-Infective Drug Studies Require Integrated Analysis

Anti-infective compounds differ widely in clearance route, matrix behavior, active forms, and mechanism-linked response. A useful analytical workflow should connect the drug class with the right analytes, matrices, transformation routes, and readouts.

From drug class to study-ready workflow

💊

Parent drug or classAntibiotic, antiviral, antifungal, antiparasitic, or proprietary anti-infective compound.

🧪

Analyte setParent compound, active metabolites, degradation products, intracellular forms, or pathway-linked endogenous markers.

📍

Matrix and exposure contextPlasma, urine, tissue, infection-site samples, intracellular extracts, or other study-specific matrices.

📊

Analytical outputQuantitative exposure data, MetID findings, stability insights, or biomarker-linked interpretation.

Antibiotic studies

Often emphasize parent-drug exposure, renal excretion, tissue penetration, hydrolysis, degradation products, and inflammation-linked response markers.

Antiviral studies

May require active metabolite analysis, intracellular exposure, phosphorylated forms, viral-response readouts, and immune pathway markers.

Antifungal studies

Frequently focus on parent-drug monitoring, CYP-related metabolism, interaction potential, tissue distribution, and matrix-specific bioanalysis.

Antiparasitic studies

Can involve parent–metabolite profiling, active metabolite confirmation, tissue exposure assessment, and host–pathogen response interpretation.

How Creative Proteomics uses this framework

This page serves as the main entry point for anti-infective drug-related DMPK and bioanalytical services, helping researchers move from a broad drug category to a more specific analytical strategy.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →